Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 27, 2012

View Archived Issues

Korean researchers patent new fusion proteins for fibrosis

Epizyme designs novel EZH2 inhibitors

New double-stranded siNA molecules disclosed by Johns Hopkins University

Stem CentRx prepares novel modulators of ephrin-A

Antares Pharma reports data from actual human use study of Vibex methotrexate

Seattle Genetics and Millennium complete enrollment in phase III AETHERA trial

Novel hPASK inhibitors patented by Bioenergenix

Results from first-in-human trial of Dz13 reported

Minicircle plasmid DNA vector successfully treats liver disease in mice

Roche patents new inhibitors of Mdm2/p53

Oral FluCide candidates demonstrate efficacy in H3N2 influenza A virus model

MediBIC signs agreement with Virginia Commonwealth University for RSR-13

Cellceutix set to commence clinical trials with Kevetrin following IRB approval

NIH launches DEX-M74 trial for hereditary inclusion body myopathy

FDA advisory committee to review Ampligen NDA

Beta-amyloid 17 identified as a potential blood biomarker of early Alzheimer's disease

RXi Pharmaceuticals completes dosing in first phase I trial of RXI-109

Ohr Pharmaceutical commences phase II trial of squalamine eye drops in wet AMD

Vertex reports new data for two nucleotide analogues in patients with hepatitis C

Mallinckrodt enters definitive agreement to acquire CNS Therapeutics

Teijin Pharma describes novel anticoagulant molecules

biOasis presents preliminary toxicity results for BT-2111

Regeneron's Eylea receives second U.S. approval

Enrollment completed in phase II trial of novel therapeutic for critical limb ischemia

Navidea receives complete response letter from FDA regarding Lymphoseek NDA

Recruitment completed in phase III studies of nintedanib in IPF